Redburn Atlantic downgraded CME Group to Neutral from Buy with a $244 price target Following the recent recovery in the share price from recent lows, CME’s risk/reward looks more balanced, the analyst tells investors in a research note. The firm is also concerned that the optics of initial share gains at FMX, the newly launched interest rates futures, in the interim may restrict any potential valuation rebound in the shares over the next 12 months. Redburn awaits for the competitive overhang to be lifted before recommending the shares again.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group price target raised to $240 from $225 at Piper Sandler
- CME Group downgraded to Neutral from Buy at Redburn Atlantic
- CME Group price target raised to $219 from $209 at Barclays
- CME Group price target raised to $250 from $240 at Citi
- CME Group price target raised to $180 from $177 at BofA